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Objectives: We sought to determine whether cardiac transplant recipients 
who required a bridge to transplantation with an implantable l ft ventric- 
ular assist device had a different outcome than patients who underwent 
transplantation without such a bridge. Methods: A retrospective study of 
256 cardiac transplants from 1992 to 1996 included 53 patients who 
received the HeartMate left ventricular assist device and 203 patients who 
had no left ventricular assist device support. Results: Left ventricular assist 
device transplants increased from 8% of all transplants in 1992 (n = 63) to 
32% in 1995 (n = 65) and 43% in 1996 (n = 14 year to date). Patients with 
and without left ventricular assist device had similar age and sex distribu- 
tions. Left ventricular assist device recipients were larger (body surface 
area 1.96 vs 1.86 m 2, p = 0.004). They were more likely to have ischemic 
cardiomyopathy (70% vs 45%, p = 0.001) and type O blood group (51% vs 
34%, p = 0.06). All patients with left ventricular assist device and 42% of 
those without had undergone previous cardiac operations by the time of 
transplantation (mean number per patient 1.5 vs 0.3, p < 0.001). More 
patients in the left ventricular assist device group had anti-HLA antibodies 
before transplantation (T-cell panel reactive antibody level > 10% in 66% of left 
ventricular assist device group vs 15% of control group, p < 0.0001). Waiting 
time was longer for the left ventricular assist device than for patients in status 
I without a left ventricular assist device (median 88 vs 37 days, p = 0.002). 
There was no difference in length of posttransplantation h spital stay (median 
15 days for each) or operative mortality (3.8% vs 4.4%). Mean follow-up 
averaged 22 months. No significant difference was found in Kaplan-Meier 
survival estimates. One-year survival was 94% in the left ventricular assist 
device group and 88% in the control group (difference not significant). 
Comparison of posttransplantation events howed no significant difference in 
actuarial rates of cytomegalovirus infection (20% vs 17%) or vascular rejection 
(15% vs 12%) at 1 year of follow-up. Similar percentages of patients were free 
from cellular rejection at 1 year of follow-up (12% vs 22%, p = 0.36). 
Conclusions: Left ventricular assist device support intensified the donor 
shortage by including recipients who otherwise would not have survived to 
transplantation. Bridging affected transplant demographics, favoring patients 
who are larger, have ischemic cardiomyopathy, have had multiple blood 
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transfusions and complex cardiac operations, and are HLA sensitized. 
Successfully bridged patients wait longer for a transplant than do UNOS 
status I patients without such a bridge, but they have similar posttrans- 
plantation hospital stay, operative mortality, and survival to those of 
patients not requiring left ventricular assist device support. (J Thorac 
Cardiovasc Surg 1996;112:1275-83) 
S tudies from the Cardiac Transplant Research Database and the Registry of the International 
Society for Heart and Lung Transplantation con- 
tinue to list the use of mechanical ventricular assis- 
tance as a risk factor with a significantly negative 
impact on survival to transplantation a d on 1 year 
survival after cardiac transplantation. 1'2 Recent 
studies from several centers, however, have shown 
comparable survivals after transplantation between 
patients who underwent bridge to transplantation 
with left ventricular assist devices (LVADs) and 
patients who did not have an LVAD bridge. 3-7 
As our experience with LVADs accrued, we noted 
that an increasing percentage of our patients under- 
going transplantation were receiving LVAD sup- 
port. It was also our impression that the subgroup of 
patients requiring LVAD support had an increased 
number of risk factors that could lead to a poor 
outcome. We therefore sought to determine 
whether cardiac transplant recipients who required 
a bridge to transplantation had different outcomes 
than did patients who did not require bridging with 
LVAD support. 
Material and methods 
Patient selection. The retrospective study comprised 
256 cardiac transplant recipients at the Cleveland Clinic 
Foundation from January 1992 to February 1996, includ- 
ing 53 patients (21%) who were bridged with the Heart- 
Mate LVAD (Thermo Cardiosystems, Inc., Woburn, 
Mass.) and 203 patients (79%) who did not require 
bridging with LVAD support. During the period of the 
study, 11 additional pediatric transplants (16 years old or 
younger) and five adult second transplants were per- 
formed; these were excluded from the analysis. The 
decision to implant he LVAD was prompted by progres- 
sive deterioration of the patient's hemodynamics and 
organ function. The hemodynamic indications for LVAD 
use included patients accepted as transplant candidates 
who had a pulmonary capillary wedge pressure of 20 mm 
Hg or greater, coupled with either a cardiac index of 2.0 
L/rain 1. m 2 or less or a systolic blood pressure of 80 mm 
Hg or less, despite maximal inotropic and intraaortic 
balloon pump support. 6Details of the device description 
and implantation technique have been reported else- 
where ,  s- I° The patients received 325 mg aspirin once a day 
throughout the period of support. The pneumatic Heart- 
Mate device was used in 41 LVAD-bridged transplants 
and the vented electric HeartMate device was used in 12. 
Five patients who underwent transplantation after bridg- 
ing with the electric HeartMate device became outpa- 
tients during support. 
Informed consent was obtained from all the patients or 
their families. All LVAD enrollment protocols were ap- 
proved by the Cleveland Clinic Foundation Institutional 
Review Board. An investigational device exemption was 
granted by the Food and Drug Administration for use of 
the pneumatic HeartMate LVAD (since approved) and 
the vented electric HeartMate LVAD. 
Transplant outcome analysis. The transplant recipi- 
ents were divided into two groups: those who received an 
implantable LVAD as a bridge to transplantation (LVAD 
group) and those who did not require bridging with an 
implantable LVAD (Non-LVAD group). The latter group 
was further subdivided into two subsets of patients: those 
who were listed at the time of transplantation as status I
on the United Network for Organ Sharing (UNOS) 
allocation list (status I group) and those listed as status II 
(status II group). 
In both groups, maintenance immunosuppression con- 
sisted of a three-drug combination of cyclosporine, aza- 
thioprine, and prednisone. Patients with compromised 
renal function were selectively treated with OKT3 mono- 
clonal antibody for induction, followed by conversion to 
cyclosporine-based immunosuppression when renal func- 
tion improved. Cellular rejection was evaluated according 
to the grading system adopted from the criteria of Bill- 
ingham and coworkers 11 and the criteria of the Interna- 
tional Society for Heart and Lung Transplantation, 12
whereby International Society for Heart and Lung Trans- 
plantation grades 1A, 1B, and 2 were considered mild 
rejection; grades 3A and 3B were considered moderate 
rejection; and grade 4 was considered severe rejection. 
Only patients who had moderate or severe rejection were 
considered in the forthcoming analysis of cellular rejec- 
tion. The diagnosis of vascular ejection was based on the 
demonstration of immunoglobulin and complement on 
the coronary vascular endothelium by immunofluorescent 
staining, according to the criteria defined by Hammond 
and colleagues, 13' 14 in addition to evidence of endothelial 
cell swelling and activation on light microscopy. Immuno- 
fluorescent staining was performed on all endomyocardial 
biopsy specimens in the first month after transplantation 
and on specimens from patients who showed persistent 
findings of vascular ejection or hemodynamic compro- 
mise during follow-up. 15' 16 
Graft coronary artery disease was defined as the devel- 
opment of new arteriosclerosis n the cardiac allograft 
compared with a baseline coronary angiogram or intra- 
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Table I. Annual distribution of 256 cardiac transplants at the Cleveland Clinic Foundation from January 1992 
to February 1996 
1992 1993 1994 1995 1996" Total (1992-1996) 
LVAD implants 8 15 13 32? 9:) 77§ 
LVAD transplants 5 l0 11 21 6 53 
Non-LVAD transplants 58 45 48 44 8 203 
Total transplants 63 55 59 65 14 256 
*Jant}ary and February. 
tTwo patients continued on support. 
:~Nine patients continued on support. 
§Eleven patients continued on support. 
vascular ultrasonographic study done before discharge 
from the hospital. All patients except those who were 
cytomegalovirus (CMV) seronegative and who received a
cardiac allograft from a CMV-seronegative donor eceived a 
4-week course of gancyclovir prophylaxis against CMV in- 
fection. CMV hyperimmune globulin was also administered 
to CMV-seronegative recipients who received an organ from 
a donor whose CMV serologic status was positive. 
Leukocyte-depleted blood (centrifuged or filtered) was 
administered in most cases during support and was routinely 
administered after transplantation. We retrospectively de- 
fined two subsets of patients, who received less than or more 
than the median umber of blood transfusions before trans- 
plantation, to determine the effects of blood use on the 
development of HLA sensitization. A T-cell panel reactive 
antibody (PRA)level greater than 10% was chosen to be 
indicative of sensitization, s7Septicemia, defined by positive 
blood culture results, elevated white blood cell count, and 
fever, combined with the need for antimicrobial treatmentl 5 
was considered related to LVAD when the same organism 
was detected in the device drive line or pump. < ~8 
Statistical Analysis. Comparison of demographic and 
clinical factors between the patients who received LVAD 
support and those who did not was performed and asso- 
ciations were analyzed with the )(2 test. Distributions of 
continuous factors were compared with the Wilcoxon 
rank-sum test. Kaplan-Meier survival estimates were com- 
pared with the log-rank test. Similar actuarial curves were 
used to compare freedoms from rejection and coronary 
artery disease in the two groups. Ap value lower than 0.05 
was considered statistically significanL 
Results 
Demographic analysis. The donor characteristics 
of the LVAD and non-LVAD groups were similar. 
The mean donor age was 30 years (median 28 years) 
in the LVAD group and 31 years (median 29 years) 
in the non-LVAD group. There were 37 male 
donors for the LVAD group (70%) and 139 male 
donors for the non-LVAD group (68%, not signifi- 
cant (NS)). Donor CMV serologic results were 
positive in 54% of the LVAD group (27/53) and in 
55% of the non-LVAD group (112/203, NS). The 
average ischemic time was significantly longer in the 
LVAD group (157 vs 140 minutes, p = 0.007). 
Table I shows the annual distribution of cardiac 
transplants from January 1992 to February 1996. A 
gradual increase in the annual percentage of trans- 
plants that were bridged with LVAD support is 
noted. LVAD-bridged transplants increased from 
8% of all transplants in 1992 (n = 63) to 32% in 
1995 (n = 65) and 43% in 1996 (n = 14, year to 
date). LVAD and non-LVAD groups had similar 
age and sex distributions (Table II). LVAD recipi- 
ents had greater mean body weight and body surface 
area. Ischemic cardiomyopathy was more common 
in the LVAD group than in the non-LVAD group. 
All patients in the LVAD group and 42% in the 
non-LVAD group had previous cardiac operations 
before transplantation. The mean numbers of pre- 
vious cardiac operations per patient were 1.5 and 
0.3, respectively (p < 0.001). Those in the LVAD 
group were more likely to have type O blood group 
(51%) than were those in the non-LVAD group 
(34%, p = 0.06). All patients in the LVAD group 
and 62% in the non-LVAD group (126 patients) 
were UNOS status I at the time of transPlantation 
(Table III). The duration of LVAD support before 
transplantation ranged from 3 to 153 days (median 
72 days). Times on the waiting list were 88 days for 
the LVAD group, 37 days for non-LVAD group 
patients who were in UNOS status I (p = 0.002) and 
118 days for patients in the non-LVAD group who 
were in UNOS status II (NS). Survival to transplan- 
tation did not differ between the LVAD and non- 
LVAD groups. The transplantation rate was 80% 
for the LVAD group on the waiting list and 84% for 
the non-LVAD group (NS). 
Septicemia occurred in 45% of patients who had a 
bridge to transplantation attempted (35/77) and in 
51% of patients with successful bridge to transplan- 
tation (27/53). Septicemia resulted from device- 
related infection in 42% of patients who had a 
bridge to transplant attempted (32/77) and in 40% 
of patients with successful bridge to transplantation 
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Table II. Demographic Description of the 256 
cardiac transplants by group, (%) 
LVAD Non-LVAD 
Variable (n = 53) (n = 203) p 
Age (yrs) 
Mean 53 50 NS 
Median 53 53 
Range 34-66 1%66 
Sex 
Male (%) 46 (87) 155 (76) NS 
Female (%) 7 (13) 48 (24) 
Body weight (kg) 82 73 0.0005 
BSA (m 2) 1.96 1.86 0.004 
Diagnosis 
ICM (%) 37 (70) 91 (45) 0.001 
Non-ICM (%) 16 (30) 112 (55) 
Previous cardiac 53 (100) 84 (42) 0.001 
operations (%) 
Blood group (%) 
A 16 (30) 97 (48) 
AB 2 (4) 14 (7) 
B 8 (15) 23 (11) 
O 27 (51) 69 (34) 0.06 
UNOS status I (%) 53 (100) 126 (62) 0.001 
Median waiting 88 58 0.07 
time (days) 
Listed UNOS status I 73 37 <0.01 
Duration of LVAD 72 
support 
Median blood products 
(units)* 
On LVAD support 96 
At transplantation 17 5 0.0001 
T-cell PRA >10% 27/41 (66%) 25/169 (15%) <0.0001 
140/203 (69) 0.04 CMV seropositivity (%) 40/48 (83) 
BSA, Body surface area; ICM, ischemic cardiomyopathy. 
*Blood products included packed red blood cells, platelet concentrates (1 
pack - 6 units), fresh-frozen plasma, and cryoprecipitate (1 pack - 20 
units). 
(21/53). Seventy-seven percent of the patients who 
had septicemia during LVAD support survived to 
transplantation (27/35 patients), compared with 
84% of the patients who did not have septicemia 
during support (26/31 patients, NS). 
More patients in the LVAD group had anti-HLA 
antibodies before transplantation (T-cell PRA level 
>10% in 66% of the LVAD group vs 15% of the 
non-LVAD group, p < 0.0001). The mean peak 
T-cell PRA level in the LVAD group was 33%, 
compared with 4% for the non-LVAD group (p < 
0.001 ). Blood use during LVAD support of more 
than 96 units of blood products (median) resulted in 
a significantly larger number of patients who were 
sensitized than did blood use less than the median 
(T-cell PRA level >10% in 74% vs 58%,p < 0.05). 
A significantly higher level of sensitization against 
Table III. Outcome of the 256 cardiac transplants 
by group, (%) 
LVAD Non-LVAD 
Variable (n = 53) (n = 203) p 
Posttransplantation 
LOS (days) 
Mean 18 18 NS 
Median 15 15 
Reexplored for 3 (5.7) 9 (4.4) NS 
bleeding after 
transplantation 
(%) 
30-day operative 2 (3.8) 9 (4.4) NS 
mortality (%) 
Mean follow-up 17 23 0.01 
(months) 
Survivors (%) 48 (91) 174 (86) NS 
Posttransplantation 
events at 1 yr 
(%) 
CMV infection 20 17 NS 
rate 
Vascular ejec- 15 12 NS 
tion rate 
Moderate and 12 22 NS 
severe rejec- 
tion-free 
Transplant CAD 90 88 NS 
free 
LOS, Length of stay; CAD, coronary artery disease. 
HLA antigens was also noted (mean peak T-cell 
PRA level 49% vs 22%, p = 0.01). 
Transplant outcome analysis. Table III shows 
the transplant outcomes of the two groups. There 
was no significant difference in length of posttrans- 
plantation hospital stay between the two groups. 
The 30-day operative mortality rates were also sim- 
ilar (3.8% vs 4.4%, NS). Mean follow-up after 
transplantation for the two groups averaged 22 
months, i7 months for the LVAD group and 23 
months for the non-LVAD group (p = 0.01). There 
was a survival of 91% in the LVAD group (48/53) 
and a survival rate of 86% in the non-LVAD group 
(174/203) at the time the study was concluded. No 
significant difference was found in the actuarial 
Kaplan-Meier survival curves between the LVAD 
group and the UNOS status I and II non-LVAD 
groups at 3 years (Fig. 1). One-year survival was 
94% in the LVAD group, versus 91% and 86% in 
the UNOS status I and II non-LVAD groups, 
respectively (NS). 
Comparison of posttransplantation events howed 
no significant difference between the LVAD and 
non-LVAD transplant groups with respect o inci- 
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PATIENT SURVIVAL AFTER TRANSPLANT 
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Fig. 1. Kaplan-Meier survival curves for transplant recipients with or without LVAD bridge to transplan- 
tation. 
dence of CMV infection (10/53 vs 30/203 patients) 
and vascular ejection (7/53 vs 28/203 patients) at 
the end of follow-up. The actuarial Kaplan-Meier 
estimates of the rate of CMV infection and vascular 
rejection in the LVAD and non-LVAD groups were 
not significantly different at 1 year of follow-up 
(Table III). Rates of freedom from transplant cor- 
onary artery disease were similar at 1 year of 
follow-up (90% vs 88%, NS). Rates of freedom from 
moderate and severe cellular rejection were also 
similar for the two groups (Fig. 2). The mean 
numbers of moderate and severe rejection episodes 
in the two groups at 12 weeks were !.68 and 1.47; at 
1 year, they were 2.53 and !.99 episodes (NS). 
Discuss ion 
Patients who require preoperative bridging have 
longer waiting times, approximately 138% longer 
than status I patients who do not require mechanical 
bridging. The reason for this longer wait is multifac- 
torial. Most of our patients with LVAD implants are 
inactive on the waiting list for approximately 4 
weeks during which the marginal state of their vital 
organ function is reversed, along with their muscle 
wasting and malnutrition from cardiac cachexia. 
Furthermore, LVAD recipients are at a higher risk 
for sensitization against HLA antigens 19 because of 
the large number of blood products that they re- 
ceive, and they may therefore require a longer wait 
to identify a satisfactory match in an altograft donor. 
In our experience, cardiac allograft donors for 
LVAD recipients have similar age to donors for 
non-LVAD recipients and are subjected to a longer 
ischemic time than are those in the latter group. 
This indicates that the comparable survival among 
LVAD transplant recipients was not a result of a 
preferential selection of the best local cardiac allo- 
graft donor from the UNOS allocation list; rather, it 
reflected these recipients' improved physical condi- 
tion at the time of transplantation. 
Patients who received an LVAD as a bridge to 
transplantation received a large number of units of 
blood products. Several factors contributed to the 
extensive perioperative blood use. Forty-nine per- 
cent of LVAD recipients had undergone previous 
cardiac operations by the time of LVAD implanta- 
tion, and all had previous sternotomies at the time 
of transplantation. Data from our center indicate 
that hepatic dysfunction as a result of right ventric- 
ular failure or as a component of developing multi- 
organ dysfunction contributed to the perioperative 
state of coagulopathy that developed in some of 
these patients. Thrombocytopenia, in conjunction 
with heparin-associated antibodies, was observed in 
40% of all patients in whom an LVAD bridge to 
transplantation was attempted. We maintained 
LVAD recipients on a regimen of platelet-inhibiting 
agents during support and have found that they are 
likely to have complications of peptic ulcer disease, 
including upper gastrointestinal bleeding necessitat- 
ing multiple blood transfusions. About 15% of our 
patients in whom bridge to transplantation was 
attempted had abdominal complications necessitat- 
ing operative intervention. Severe device-related 
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Fig. 2. Actuarial freedom from rejection (%) of the patients with and without LVAD bridge to 
transplantation. Deaths were censored. 
hemorrhage occurred in an additional 8%, necessi- 
tating emergency operative intervention and multi- 
ple blood transfusions. 
Although LVAD recipients were in cardiogenic 
shock before bridging, had multiple blood transfu- 
sions and infections during support, and underwent 
complex reoperations, LVAD support did not have 
a negative influence on the posttransplantation h s- 
pital course and did not adversely affect survival 
after transplantation. Our present experience with 
the implantable LVAD as a bridge to transplanta- 
tion agrees with other reports demonstrating that 
survival of patients who require mechanical circula- 
tory suppor t for bridging is equivalent to that of the 
cohort of patients not requiring mechanical circula- 
tory support. 4'5, 2o Our study also shows no signifi- 
cant differences in posttransplantation le gth of 
hospital stay and operative mortality between the 
LVAD and the non-LVAD groups. 
Patients in the LVAD group were larger and 
more likely to have type O blood group. It has been 
observed from the UNOS database that the median 
waiting time for larger patients with type O blood 
was 319 days in 1993 and that the percentage of 
deaths on the waiting list was higher in that group. 5
It is likely that a larger number of these patients will 
progress to UNOS status I while waiting because of 
their longer waiting times, and they are therefore 
more likely to need mechanical support. For these 
patients, we recommend the use of a portable, 
battery-powered lectric system to facilitate early 
discharge from the hospital to reduce hospital costs 
and to improve patient mobility and quality of life 
during this longer wait. We reported elsewhere 19
that patients with LVAD bridging are at increased 
risk for development of anti-HLA antibodies as a 
result of the multiple blood transfusions they receive 
during support. In this study, we could not demon- 
strate any association between HLA sensitization 
from blood use during LVAD support and the 
occurrence of vascular and cellular ejection or the 
number of rejection episodes at one-year of follow- 
up. However, the larger number of blood products 
that LVAD patients received may have contributed 
to their higher rate of positive CMV serologic 
results before transplantation. A larger patient co- 
hort and a longer period of follow-up are required 
to determine the impact of the extensive blood use 
in LVAD recipients on the rate of CMV infection 
after transplantation. 
Although the number of patients undergoing 
transplantation at our institution has not changed 
significantly during the past 4 years, the frequency of 
LVAD use has increased remarkably and accounted 
for one third of the cardiac transplants performed in
1995. Because the competition for scarce organ 
donors is increasing and LVAD recipients have high 
priority as status I patients, this trend will probably 
continueY The implications for the cost of the 
cardiac transplantation process are important. The 
costs of two operations for patients with this bridge 
(LVAD insertion and transplantation) are higher 
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than the costs of transplantation alone for patients 
who do not need bridging with LVAD support. 
Our data summarize a single center's experience 
with the implantable LVAD as a bridge to trans- 
plantation. This study thus avoids the bias seen with 
multiinstitutional studies, with potentially different 
patient selection criteria and management before 
LVAD implantation, during support, and after car- 
diac transplantation. The study was limited, how- 
ever, by the fact that the non-LVAD group com- 
pared with the LVAD group was neither blinded 
nor randomized. A drawback of this study is the 
difference in the mean period of follow up between 
the two groups. A longer period of follow-up will 
provide further insight into the incidence of viral 
and nonviral infections after transplantation, aswell 
as the impact of sensitization during bridging on the 
long-term incidence of rejection and graft arterio- 
sclerosis. 
Conclusion 
LVAD support intensified the donor shortage by 
keeping alive recipients who otherwise would not 
have survived to transplantation. Bridging affected 
transplant demographics, favoring patients who are 
larger, have ischemic ardiomyopathy, have multiple 
blood transfusions and complex cardiac operations, 
are HLA sensitized, and have longer graft ischemic 
time. Patients with successful bridging wait longer 
for transplantation than do patients in UNOS status 
I without bridging but have similar posttransplanta- 
tion hospital stays and operative mortality rates, 
with survival also similar to that of patients not 
requiring LVAD support. The need for LVAD 
support is not a marker of poor outcome after 
transplantation, and the impact of bridging on long- 
term outcomes needs further follow up. 
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Discussion 
Dr. Eric A. Rose (New York, N.Y.). I congratulate you 
and your colleagues at the Cleveland Clinic for your 
excellent results in this challenging patient population 
with heart failure. It seems clear that this experience is
dramatically altering the composition of the transplant 
recipient pool to include an increasing proportion of 
device-dependent patients, now exceeding 40% of those 
receiving transplants at your institution. You also point 
out that device use remains an imperfect technology, with 
persistent problems including anti-HLA sensitization and 
septicemia, although thromboembolism is now remark- 
ably infrequent. 
The increasing success in bridging to transplantation 
also creates difficult dilemmas in managing the enlarging 
pool of potential transplant candidates. Bridging to trans- 
plantation does not increase the number of transplants 
performed; rather, it shifts the donor pool away from 
patients who do not have bridging. You point out that 
your increasingly frequent use of bridging has intensified 
the donor shortage at your institution. Furthermore, 
bridging to transplantation is an expensive process that 
may not be fully reimbursable for many patients. Regard- 
less of these concerns, increasing experience in extended 
duration of bridging to transplantation brings us ever 
closer to using these devices as what may be called 
"destination therapy." 
In our bridge experience with 80 patients at Columbia- 
Presbyterian Medical Center, we were able to explant 
devices because of recovery of left ventricular function in 
three patients. Two of these three patients survived in 
short-term follow-up; the third died of rapidly progressive 
left ventricular failure associated with a viral syndrome 2
months after explantation. We believe that an as yet 
undefined subset of patients with bridging may spontane- 
ously recover with temporary device support, without the 
need for transplantation. 
I have four questions. First, have you been able to 
explant any devices from patients without transplanta- 
tion? Second, can you specifically identify a recipient 
population without bridging on your waiting list with 
deterioration or death because of the increasing use of 
mechanical assistance? Or has improving medical man- 
agement of your prospective r cipient pool overcome this 
thorny issue? Third, have you compared costs for the 
patients with bridging with those of both status I and 
status II patients without bridging in this series? Finally, 
do you envision the indefinite deferral of transplantation, 
either because of patient preference or because of increas- 
ing competition for donors, in the near future? 
Dr. Rieardo Moreno-Cabral (San Diego, Calif.). I also 
congratulate you for sharing your data with us. We have 
implanted 16 Thermo Cardiosystems pumps--12 pneu- 
matic and four vented electric--and have performed 
transplantation in 11 of these patients. Our survival results 
are quite similar to those presented today. 
My questions relate to the subgroup of patients with a 
high percentage of PRAs. We have a patient whose PRA 
levels have been greater than 90% and who has been 
assisted for now 405 days, probably the longest time a 
patient has been assisted with a pneumatic Thermo Car- 
diosystems device. The first question is, have you modified 
your immunosuppression protocols for this subgroup of 
patients? The second is, have you noted any evidence of 
early graft atherosclerosis or decreased 2- to 3-year sur- 
vival after transplantation among patients with high PRAs 
or a positive crossmatch result? 
Dr. J. Donald Hill (San Francisco, Calif.). I congratulate 
you and the Cleveland Clinic group on your excellent 
work. Your conclusions upport he other reported expe- 
rience in bridge to transplantation; that is, the short- and 
long-term results in LVAD-supported patients are similar 
to those of patients who only undergo cardiac transplan- 
tation, and especially that donor hearts are not wasted. I 
suggest, however, that in 1996 the question is not whether 
one can successfully bridge a patient to transplantation 
with an LVAD in a select group of patients but whether 
one can bridge all patients who require support? 
In your series, 53 patients received LVAD support. 
How many emergency patients or patients on the trans- 
plant waiting list whose condition deteriorated id not 
qualify for LVAD support for medical reasons (e.g., 
patient size, right heart failure, arrhythmias, liver failure)? 
All of these comorbidities/conditions present special 
problems for LVADs. The question confronting surgeons 
today is not whether one cannot support carefully selected 
patients, but how one can support patients who manifest 
the late signs of congestive heart failure without utilizing 
biventricular support. 
Dr. Cliff Van Meter (New Orleans, La.). I echo the 
congratulations for your outstanding result in this chal- 
lenging group of patients both with and without LVAD 
support. Our experience in New Orleans has been a bit 
different. In a similar period, we did slightly in excess of 
200 transplants. We used LVAD in 12. One did not 
survive the attempted ventricular support, 10 successfully 
underwent transplantation a d are survivors, and one is 
receiving ongoing support. In our area, in excess of 85% of 
transplants are done in status I patients. We do trans- 
plants in very few status II patients. Some questions till 
remain regarding the optimal timing, not only of LVAD 
support but also of transplantation after LVAD support. 
To help in clarifying some of those questions, I have two 
questions. First, what was the status I patient waiting list 
mortality in the non-LVAD group? Second, excluding 
status II patients, was there a significant difference be- 
tween posttransplantation hospital stays of the status I
LVAD group versus the non-LVAD patient population? 
More specifically, we have found a remarkably shorter 
posttransplantation h spital stay among those with LVAD 
support versus those without. 
Dr. Massad. I thank the discussants for their comments. 
To answer Dr. Rose's first question, we have not been able 
to explant any devices from patients without transplanta- 
tion as a result of recovery of their native myocardium. In 
response to your second question, although it is hard for 
me to recall a status I transplant candidate without 
bridging who had deteriorated condition or died merely 
because of lack of a donor as a result of the use of 
mechanical assistance, I concur that the improvement in
the medical management of our prospective transplant 
recipient pool has played a major role in overcoming this 
problem. In addition to that, and to accommodate the 
group of LVAD recipients, we have expanded our donor 
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selection criteria to include those who were considered 
"marginal donors," without a demonstrably negative im- 
pact of the use of those so-called "marginal donors" on 
survival. I do recall that we had six status II patients whose 
symptoms progressed and required LVAD support in our 
transplant group. With respect o cost, I believe at our 
institution the median cost of a bridged transplant is 
almost wice that of a nonbridged transplant. I am certain 
that cost is going to be a significant issue in the near 
future. I envision the indefinite deferral of transplantation 
with future improvements in circulatory assistance tech- 
nology. 
To answer Dr. Moreno-Cabral's questions, we bad few 
patients who had high PRA levels during LVAD support 
and were able to deal with them on individual basis. We 
do not routinely perform prospective crossmatching on all 
our transplant candidates. With respect to the highly 
sensitized LVAD recipients, we assume that they are 
going to be seropositive and deal with that accordingly. 
We subjected four such patients (mean PRA 97%) to 
plasmapheresis during support when they were high on 
the waiting list to provide a window for them to undergo 
transplantation; with that, we were able to drop their 
quantitative antibody levels by 77%, as measured by flow 
cytometric analysis. We perform retrospective cross- 
matching on all our patients after transplantation and 
have modified the immunosuppression protocol in the 
highly sensitized group to include induction with mono- 
clonal antibodies (OKT3) for 2 weeks and continued 
plasmapheresis after transplantation for 3 to 4 weeks. We 
have also added cyclophosphamide or mycophenalate 
mofetil instead of azathioprine. From the data that I have 
presented, early graft arteriosclerosis and actuarial sur- 
vival estimates in the overall sensitized LVAD recipients 
and the nonbridged transplant recipients were similar. 
I echo the concerns of Dr. Hill with respect o the 
patients manifesting the late signs of congestive heart 
failure, who form a more challenging roup. However, in 
most of our LVAD-bridged patients we were able to 
reverse the state of right heart failure with inotropes and 
pulmonary vasodilators. Right heart failure necessitated 
temporary implantation ofa right ventricular-assist device 
in only 12% of our transplant recipients. In this subset of 
patients, the need for a right ventricular-assist device was 
a marker of poor outcome; it was associated with a 
significantly lower transplantation rate. Approximately 
one of every eight deaths among our LVAD recipients 
was a result of right ventricular failure necessitating right 
ventricular-assist device support. 
To answer the questions that Dr. Van Meter raised, the 
mortality for the UNOS status I listed patients without 
bridging while waiting was not different from that of 
LVAD recipients. The mean posttransplantation hospital 
stays of both groups were also similar. 
